Hims & Hers: The Long View
What the filings say about its story, dilution and cash runway.
Disclosure: one or more of our editors own shares of Hims & Hers (HIMS) as a long-term investment. This page is information, not investment advice.
1. In one paragraph
Last updated Nov 11, 2026. Reflects the 10-K for 2025 and the 10-Q for Q3 2026.
Hims & Hers sells subscription treatments online for sexual health, hair loss, weight loss, skin, hormones and mental health, plus lab testing. Most revenue is recurring subscription billing paid directly by consumers. The United States was 94% of 2025 revenue, but acquisitions abroad took the rest of the world to 20% in the first nine months of 2026.
- A customer fills in an online questionnaire. A licensed provider from the company’s affiliated medical groups prescribes if appropriate, and the company’s own or partner pharmacies ship the product.
- The company reports one operating segment and gives revenue by geography (10-Q Q3 2026).
- It says its international operations include the UK, Australia, Canada, France, Germany, Ireland, Spain and Japan, following acquisitions including Zava, Livewell and Eucalyptus (8-K).
| Revenue (disclosed) | 2025 | Share | First nine months of 2026 | Share |
|---|---|---|---|---|
| United States | $2,213.6M | 94% | $1,808.8M (+9%) | 80% |
| Rest of world | $134.0M | 6% | $442.9M | 20% |
| Total | $2,347.6M (+59%) | $2,251.7M (+30%) |
Other disclosed mix facts:
- The Hers brand was nearly 40% of US revenue in 2025 and about 45% in Q3 2026.
- “Personalized” treatment plans, which may include compounded formulas (medicines a pharmacy mixes for an individual patient), were over 70% of 2025 US revenue.
- A majority of US revenue came from non-GLP-1 offerings (GLP-1 drugs mimic a hormone involved in appetite and blood-sugar control) in both 2025 and the first nine months of 2026 (10-K 2025, 10-Q Q3 2026).
2. Story so far
Last updated Nov 11, 2026. Reflects filings and company releases through Nov 9, 2026.
In short: Hims listed in 2021 as an online men’s-health brand and reported $2.35B of revenue in 2025, helped by newer treatments including GLP-1 weight-loss offerings launched in 2024 (10-K 2025, Q2 2024 letter). In 2026 it moved its US weight-loss offering to branded drugs through drugmaker deals and bought Eucalyptus to grow abroad, funding the push partly with convertible notes (debt that can turn into shares); in July the Federal Trade Commission (FTC) sued it over billing and data practices, which it disputes. In November it reported 49% revenue growth for Q3 and lower gross margins, and cut its 2026 adjusted EBITDA outlook; the CFO tied the cut to price and marketing moves in the UK and Germany and to deferring some weight-loss membership revenue.
| Date | Milestone | Source |
|---|---|---|
| Jan 2021 | Lists on the NYSE through a merger with Oaktree Acquisition Corp., a special-purpose acquisition company (SPAC) | 10-K 2022 |
| Q2 2024 | ★ Launches access to GLP-1 weight-loss injections on its platform | Q2 2024 letter |
| May 5, 2025 | Sets 2030 targets: at least $6.5B revenue and $1.3B adjusted EBITDA (the company’s earnings measure before interest, taxes, depreciation, amortisation, stock pay and other items it lists) | Q1 2025 letter |
| May 2025 | Issues $1.0B of 0% convertible notes due 2030 | 10-Q Q3 2026 |
| Jul 2025 | Buys Zava (UK/EU); the $258.0M accounting purchase price includes $167.3M paid upfront and $90.7M of contingent consideration | 10-K 2025 |
| Feb 19, 2026 | Agrees to buy Eucalyptus (Australia; up to $1.15B including deferred and earn-out payments) | 8-K |
| Mar 9, 2026 | ★ Announces a Novo Nordisk collaboration to offer Wegovy and Ozempic later that month; stops advertising compounded GLP-1s and limits their availability. Novo’s Feb 9 suit over compounded semaglutide is dismissed without prejudice the same day | 8-K, 10-Q Q2 2026 |
| May 21, 2026 | Issues $402.5M of 0% convertible notes due 2032 | 8-K |
| Jun 1, 2026 | ★ Completes the Eucalyptus acquisition (announced Jun 2) | 8-K |
| Jul 29, 2026 | ★ The FTC, Utah and Los Angeles County sue over billing and data practices; the stock closes at $25.00, down 14.7% from $29.32 the previous day | 10-Q Q2 2026, Hims stock history |
| Aug 10, 2026 | Q2 revenue +38%; 2026 revenue guide raised to $3.1–3.3B, adjusted EBITDA guide narrowed to $275–325M | 8-K |
| Oct 20, 2026 | Launches the Hims brand in Germany, starting with weight-management care | Hims newsroom |
| Oct 2026 | Start of our coverage: this Long View | |
| Nov 6, 2026 | Announces an agreement with Eli Lilly to offer Zepbound and Foundayo at Lilly’s self-pay prices, and commits not to offer compounded copies of Lilly’s GLP-1s | Lilly and Hims & Hers |
| Nov 9, 2026 | Q3 revenue +49% to $890.4M; 2026 adjusted EBITDA guide cut to $257–277M. The stock closes at $19.13 on Nov 10, down 16.6% | 8-K, Yahoo Finance |
3. Latest quarter: did the story change?
Last updated Nov 11, 2026. Reflects Q3 2026 (reported Nov 9, 2026). The Q4 2026 results date has not been announced; Q4 2025 was reported on Feb 23, 2026.
Bottom line: Per its Q3 release, revenue and adjusted EBITDA landed within the company’s own Q3 guidance and free cash flow (operating cash flow less capital spending and capitalised software) turned positive, helped by selling receivables to a bank. Gross margin fell again, subscribers dropped from June, and the full-year adjusted EBITDA outlook was cut to $257–277M; the net loss was $33.0M, compared with a $15.8M profit a year earlier.
| Driver | Last quarter → this quarter | Management: before → now | Signal |
|---|---|---|---|
| Revenue | $753.2M (+38%) → $890.4M (+49%); US +16% → +21%; rest of world $131.4M → $233.3M | Q3 guide $880–900M (Aug 10) → actual $890.4M; 2026 guide $3.1–3.3B (Aug 10) → $3.13–3.15B (Nov 9); 2026 international revenue at least $600M → at least $650M (Nov 9 call) | Better |
| Subscribers | 2.891M → 2.788M (−3.6%)1; still +13% from a year earlier | Up 19% from a year earlier in Q2 → the CFO tied the fall to “measured marketing spend” and said holding back in Q4 “may lead to an additional quarter of subscriber count headwinds” (Nov 9 call) | Worse |
| Gross margin and adjusted EBITDA | Gross margin 64% → 57% (74% a year earlier); adjusted EBITDA $60.3M → $82.4M2 | Margin “expected to remain below comparative periods in the near term” (10-Q, Aug 10) → fell further; the CFO expects declines “to start to moderate” (Nov 9 call). 2026 adjusted EBITDA guide $275–325M → $257–277M | Worse |
| Free cash flow | −$68.2M → +$26.0M, after $433.3M from selling receivables to JPMorgan in Q3 | Expected to “resume free cash flow generation in the second half” (Aug 10 call) → positive in Q3 | Watch |
| Legal and regulatory | FTC, Utah and Los Angeles County suit (Jul 29); about $60M accrued → motion to dismiss filed Oct 22, hearing set for Jan 14, 2027; a new securities class action filed Sep 1; accrual unchanged | Negotiations with the FTC unsuccessful; will defend vigorously (10-Q, Aug 10) → “meritorious arguments”; does not currently consider a loss on the new class action probable (10-Q, Nov 9) | Watch |
Q3 adjusted EBITDA newly adds back foreign-currency losses ($4.1M); earlier quarters were not recast.
Reported: the subscriber explanation, the margin comments, the international revenue expectation and Eucalyptus’s roughly $135M Q3 contribution are attributed to CFO Yemi Okupe in The Motley Fool’s transcript of the Nov 9, 2026 call; the Aug 10 free-cash-flow expectation is from its transcript of that call. We have not verified those transcripts against a company recording.
Sources: Q2 2026 release, Q3 2026 release, 10-Q Q2 2026, 10-Q Q3 2026, Q2 2026 call transcript, Q3 2026 call transcript.
Unresolved questions:
- Weight-loss revenue and margin after the switch to branded drugs (not disclosed).
- Whether subscribers grow again after the fourth-quarter launches.
- How much of the remaining Eucalyptus deferred payments is settled in shares rather than cash.
- The outcome of the FTC case and the securities class actions.
4. Buybacks vs real dilution (5 years)
Last updated Nov 11, 2026. Reflects the equity statements in the 10-Ks for 2022 and 2025 and the 10-Q Q3 2026.
Dilution in one line: shares outstanding rose 11.0% from Dec 31, 2021 to Dec 31, 2025 (2.6% a year, compounded). If you owned 1% of Hims & Hers at Dec 31, 2021, you’d own 0.90% at Dec 31, 2025 without buying more (0.87% at Sep 30, 2026). Buybacks offset about 27% of the new shares (our calculation)3. Our scale: Moderate (1–3% a year).
Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.
Change in the period Total since Dec 31, 2021
Shares outstanding at period end (all classes): 204.8M on Dec 31, 2021, 227.2M on Dec 31, 2025, +11.0% (our calculation). A bar below zero means the count fell (net buybacks).
Latest quarter-end (Sep 30, 2026): 234.4M shares, +3.1% since Dec 31, 2025.
Class A plus Class V common stock.
| Period end | Shares outstanding | Change | Buybacks (fiscal year) | Stock-based pay (fiscal year) | Stock pay as % of revenue |
|---|---|---|---|---|---|
| FY2025 (Dec 31, 2025) | 227.2M | +2.9% | $90M | $135M | 6% |
| FY2024 (Dec 31, 2024) | 220.8M | +3.4% | $83M | $92M | 6% |
| FY2023 (Dec 31, 2023) | 213.5M | +2.4% | $2M | $66M | 8% |
| FY2022 (Dec 31, 2022) | 208.4M | +1.8% | $0 | $43M | 8% |
| FY2021 (Dec 31, 2021) | 204.8M | — | $0 | $67M | 25% |
Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.
Most new shares came from employee stock awards.
How we calculated this
The company listed in January 2021, so the bridge starts at Dec 31, 2021.
| Share bridge, Dec 31, 2021 → Dec 31, 2025 (disclosed; Class A + V) | Shares |
|---|---|
| Start | 204.79M |
| + Restricted stock units vested (net of shares withheld for tax) | +13.92M |
| + Stock options exercised | +13.00M |
| + Employee stock purchase plan | +2.11M |
| + Acquisitions and earn-outs (2024–25) | +1.39M |
| + Warrants exercised (2024) | +0.27M |
| − Repurchased and retired (2023–25; $175.0M spent) | −8.24M |
| End | 227.25M (+11.0%) |
| Shares issued on convertible notes or in stock offerings | None in the period |
Prices paid and received:
| Period | Shares bought back | Average price paid | Spent | Shares sold for cash | Average price received | Raised | Sources |
|---|---|---|---|---|---|---|---|
| 2022 | — | — | — | — | — | — | 10-K 2022 |
| 2023 | 0.24M | $8.42 (our calculation) | $2.0M | — | — | — | 10-K 2025 (equity statement) |
| 2024 | 5.77M | $14.40 (our calculation) | $83.0M | — | — | — | 10-K 2025 (equity statement) |
| 2025 | 2.23M | $40.25 (our calculation) | $90.0M | — | — | — | 10-K 2025 (equity statement) |
| 2026 to Sep 30 | — | — | — | — | — | — | 10-Q Q3 2026 |
Hims bought back 8.24M shares for $175.0M over 2023–25, about $21.24 a share on average, and sold no shares for cash; its fund-raising was debt.
- No stock splits in the period, so no adjustment is needed.
- Average price is our calculation4.
- Shares withheld for employee taxes are excluded; the company does not count them as buybacks.
- No shares were sold through public offerings or at-the-market programmes in the periods shown; the 2025 and 2026 fund-raising was convertible notes, which are debt.
- Employee-plan issuances and warrant exercises are excluded from the table.
- $225.0M of the 2025 buyback authorisation remained unused at Sep 30, 2026; the programme runs to Nov 11, 2028.
- For reference, the stock closed at $19.13 on Nov 10, 2026 (Yahoo Finance).
| Diluted shares and stock pay (disclosed; % is our calculation) | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Weighted diluted shares* | 204.5M | 209.3M | 236.8M | 258.2M |
| Stock-based pay | $42.8M | $66.1M | $92.3M | $135.2M |
| Stock pay as % of revenue5 | 8.1% | 7.6% | 6.3% | 5.8% |
*2022 and 2023 were loss years, so diluted equals basic. From 2024, diluted shares include unvested awards and options, and from 2025 also shares that could be issued on the convertible notes.
Stock-based pay was $143.5M in the first nine months of 2026, 6.4% of revenue5. The company also spent $187.2M from 2022 to 2025, and $81.2M in the first nine months of 2026, on employee taxes when shares were withheld on vesting. That reduces share issuance much as a buyback would.
At Sep 30, 2026, 234.40M shares were outstanding (226.02M Class A plus 8.38M Class V) (10-Q). The convertible notes and the Eucalyptus deferred and earn-out payments could add shares if settled in stock; no shares had been issued for Eucalyptus by Sep 30, and the $130.3M of deferred payments made by then were paid in cash.
Further possible share issuance
- About 13.6M shares for the 2032 notes if settled entirely in stock (conversion price $29.53). The company can settle in cash or a mix instead, and purchased option hedges (capped calls) are intended to reduce dilution up to an initial cap price of $50.15 (8-K).
- About 14.2M shares for the 2030 notes if settled entirely in stock (conversion price $70.67); capped calls are intended to reduce dilution up to an initial $89.95 cap price (10-K).
- Stock the company may choose to issue for a significant majority of the Eucalyptus deferred and earn-out payments, subject to contractual limits: a cap of 19.9% of Class A shares, which also counts securities issued in any financing connected with the acquisition. Deferred acquisition payments on the balance sheet were $563.1M at Sep 30, 2026, mainly Eucalyptus6; the Eucalyptus earn-out is up to $96.6M (10-Q).
5. Profit vs cash (latest FY and TTM)
Last updated Nov 11, 2026. Reflects the 10-K for 2025, the 10-Q for Q3 2026 and the company’s reconciliations.
In 2025 cash and profit diverged mainly through capital spending. In the last twelve months, an accounting loss coexists with positive adjusted EBITDA, which excludes several expenses, and free cash flow close to zero, even though Q3 operating cash flow included $433.3M from selling receivables to a bank.
| 2025 (disclosed) | TTM to Sep 30, 2026 (our calculation)7 | |
|---|---|---|
| Net income (loss) | $128.4M | −$190.8M |
| Adjusted EBITDA (company’s reconciliation) | $318.0M | $253.3M |
| Operating cash flow | $300.0M | $180.1M |
| Free cash flow8 | $57.4M | $8.2M |
The TTM adjusted EBITDA mixes definitions: from Q3 2026 the company adds back foreign-currency gains and losses, and earlier quarters were not recast.
Helps future profit or cash:
- Drugmaker discounts and rebates receivable ($345.3M at Sep 30, 2026): they lower the cost of inventory, reaching profit as the drugs are sold, and the cash arrives when drugmakers pay. The rise in receivables, largely these rebates, used $323.9M of cash in the first nine months of 2026.
Hurts future profit or cash:
- Capital spending ($89.1M on property, equipment and intangible assets plus $18.9M of software in the first nine months of 2026; $226.0M plus $16.5M in 2025): cash spent now, with its cost reaching profit gradually through depreciation.
- Accounts payable (+$351.2M in the first nine months of 2026): suppliers were paid later, which offset the receivables build; the cash goes out when the bills are paid.
- Legal accruals ($62.5M in 2026, about $60M for the FTC case): an expense now, with the cash going out only if and when claims are paid.
- Receivables sold to JPMorgan ($433.3M of net proceeds in Q3): brought collections forward into operating cash flow, so the company will not collect those amounts later, and it paid a discount. The facility allows further sales.
- Stock-based pay ($143.5M in the first nine months of 2026): a non-cash expense added back in adjusted EBITDA and operating cash flow; it dilutes ownership, and the related tax settlements still use cash (section 4).
One-off / no lasting effect:
- Restructuring tied to the weight-loss switch ($41.9M in the first nine months of 2026) and acquisition, transaction and earn-out costs ($77.6M) are excluded from adjusted EBITDA; the company notes similar expenses may recur.
- A $17.1M gain on selling an equity investment in Q3 lowered the net loss once.
The raw reconciling items
From the filings:
- Stock-based pay ($143.5M in the first nine months of 2026; $135.2M in 2025) is a non-cash compensation expense, added back in adjusted EBITDA and operating cash flow. Related tax settlements still use cash (section 4).
- Capital spending was heavy in 2025: $226.0M on property, equipment and intangible assets plus $16.5M of software. That is why 2025 free cash flow ($57.4M) was far below operating cash flow ($300.0M) (10-K). It slowed to $89.1M plus $18.9M in the first nine months of 2026 (10-Q).
- Expenses excluded from adjusted EBITDA in the first nine months of 2026 include $62.5M of legal accruals (about $60M for the FTC case), $41.9M of restructuring tied to the weight-loss switch, $77.6M of acquisition, transaction and earn-out costs and $5.6M of other non-recurring items. The company notes similar expenses may recur (10-Q).
- Working capital swung sharply. In the first nine months of 2026, receivables used $323.9M of cash, largely drugmaker discounts and rebates, while accounts payable supplied $351.2M and accrued liabilities $76.7M. Proceeds from receivables sold under the JPMorgan facility ($433.3M) are reported in operating cash flow (10-Q).
Funding: how long without new money? Self-funding: $8.2M of free cash flow in the trailing twelve months (TTM; our calculation)9, helped by the receivables sale; no debt is due within 24 months, but $478.6M of deferred acquisition payments fall due within 12 months (mainly Eucalyptus; a significant majority may be settled in stock), against $712.2M of cash, cash equivalents and short-term investments10.
Funding details
- As of Sep 30, 2026. Based on past cash flow; spending plans can change it.
- The free cash flow excludes acquisitions, deferred acquisition payments and employee share-tax payments, so it does not show that the expansion pays for itself.
- Working capital showed a $114.8M deficit at Sep 30, 2026, against a $363.2M surplus at Dec 31, 2025; the company attributes it mainly to the Eucalyptus deferred payments and says existing cash, the revolving credit facility and the receivables facility are sufficient for the next 12 months (10-Q).
- At-the-market share-sale programme: none disclosed.
Extends the runway:
- $161.0M available under the $175M revolving credit facility (three-year term from Feb 2025), which is committed money (10-Q).
Shortens the runway:
- Debt and convertible notes due within 24 months: none. The $1.0B of 0% notes mature May 15, 2030 and the $402.5M of 0% notes Jun 1, 2032.
- Acquisition payments: $563.1M of deferred acquisition payments, $478.6M of them due within 12 months (mainly the Eucalyptus instalments through about Dec 2027; $130.3M was paid in cash in 2026 to Sep 30), and $170.8M of earn-out liabilities, $86.6M of them current6 (10-Q).
- Total disclosed contractual obligations and commitments were $1,077.3M, including $607.0M payable within 12 months; these include the acquisition obligations above, operating leases and purchase commitments, so they are not additional (10-Q).
Conditional:
- An uncommitted facility to sell amounts owed to the company (receivables) to JPMorgan for cash at a discount, with a limit of $400M outstanding at any time (from Jul 1, 2026); $433.3M of net proceeds in Q3 (10-Q, 8-K).
- Up to $20.0M more of milestone payments under a peptide-manufacturing agreement ($30.0M in total, $10.0M paid), which the company expects to be triggered within 12 months (10-Q).
6. Customer and contract exposure
Last updated Nov 11, 2026. Reflects the 10-K for 2025 and the 10-Q for Q3 2026.
Supplier dependence, regulation and customer subscription practices are the main exposures: no single customer or partner was above 10% of revenue in 2023–2025, drugmakers supply the branded weight-loss drugs, and the FTC case, the FDA’s compounding proposal and telehealth rules for controlled substances are open regulatory items.
Customer and contract details
- A “significant majority” of customers are individuals buying through the company’s websites and apps. No single customer or partner represented more than 10% of revenue in 2023, 2024 or 2025. One customer or partner was over 10% of receivables at the end of 2025 (four at the end of 2024) (10-K). The filings show no separate government-revenue line.
- Drugmakers supply the branded weight-loss drugs:
- The Q3 10-Q says certain offerings are primarily fulfilled by one supplier or a limited number of suppliers; the Q2 10-Q had named weight-loss offerings and one supplier, and expected supply constraints on branded GLP-1s to continue, a sentence the Q3 10-Q drops (10-Q Q2, 10-Q Q3).
- Branded GLP-1s come through vendor supply agreements under which drugmakers owe discounts and rebates ($345.3M receivable at Sep 30, 2026).
- The Mar 2026 Novo Nordisk collaboration’s term and notice periods are not disclosed. Novo’s patent suit was dismissed without prejudice, so it can be refiled (8-K, 10-Q). On Nov 6, 2026, Lilly and Hims & Hers announced an agreement under which patients prescribed on the platform can get Zepbound and Foundayo at Lilly’s self-pay prices; Hims & Hers committed not to offer compounded copies of Lilly’s GLP-1 drugs. The announcement gives no contract length or notice period (Lilly and Hims & Hers).
- In the UK, Zava runs online-doctor services on Asda and Superdrug’s websites, and those pharmacies dispense and dispatch the medicines (10-K). Hims accounts for these platform-partner arrangements as an agent, recording revenue net (10-Q).
- Financing contracts:
- JPMorgan receivables facility: limit of $400M outstanding at any time, uncommitted, initial 364-day term from Jul 1, 2026; receivables with a carrying value of $434.5M were sold in Q3 (8-K, 10-Q).
- $175M revolving credit facility, three years from Feb 2025, amended in Aug 2026; $161.0M was available at Sep 30, 2026 (10-Q).
- Contracts with a director: Andrew Huberman joined the board in Nov 2026 as a non-independent director. He is paid $3.5M a year for two years for advisory services, plus up to $1M a year for short videos, and a podcast company he co-owns, Scicomm Media, receives $5M a year for up to three years for advertising (8-K).
- Legal and regulatory matters:
- The FTC and state plaintiffs allege deceptive billing, cancellation and health-data practices (suit filed Jul 29, 2026). Hims disputes the allegations and moved to dismiss on Oct 22; a hearing is set for Jan 14, 2027. A new securities class action, filed Sep 1, 2026, covers buyers from Aug 4, 2025 to Jul 29, 2026; separate privacy and earlier securities class actions are also disclosed (10-Q).
- On Apr 30, 2026, the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the list of bulk ingredients that outsourcing facilities may use for compounding under section 503B. It is a proposal, not a blanket ban on all compounding (FDA).
- New in the Q3 10-Q: some testosterone products the company began offering in 2026 are Schedule III controlled substances. Prescribing them by telehealth depends on temporary federal flexibilities due to expire on Dec 31, 2026 and on a pending DEA rule. A separate new risk factor says the rules for peptides are evolving (10-Q).
7. Strategy for long-term growth
Last updated Nov 11, 2026. Reflects the 10-K for 2025, the Q4 2025 shareholder letter, the Q3 2026 release and 10-Q, and the Q3 call.
Hims & Hers built its business on its own brands of personalised, often compounded, treatments sold by subscription, and regulators, drugmakers and the FTC now press on parts of that model. Its answer is to add specialties, offer branded drugs through drugmaker deals, grow abroad largely by acquisition and make more of what it sells, and in 2025 it set 2030 targets of at least $6.5B of revenue and $1.3B of adjusted EBITDA. So far revenue is growing faster than gross profit, and the company did not repeat the 2030 targets in November.
Pressure on the core business
Compounded weight-loss drugs, an early growth driver, face tighter rules, and drugmakers sell directly too.
- Compounding: in March 2026 Hims moved its US weight-loss offering to branded GLP-1 drugs, keeping compounded versions “on a limited scale”; it recorded $41.9M of restructuring charges for the switch in the first nine months of 2026 (10-Q). The FDA’s April proposal would remove three GLP-1 ingredients from the list outsourcing facilities may compound from (FDA), and Novo Nordisk’s patent suit, dismissed in March, can be refiled (section 6).
- Competition: the 10-K says no competitor offers its full range, but names fragmented telehealth rivals, pharmacies and retailers, and “certain traditional pharmaceutical companies that offer prescription products through direct-to-consumer or digitally enabled channels” (10-K). Citing third-party data, the company said it was “roughly twice the size of the next largest U.S. telehealth provider in 2025” (Q4 2025 letter).
- Regulation and legal: the FTC case over billing and data practices, telehealth rules for controlled substances that cover some testosterone products, and evolving peptide rules (section 6).
The strategy in management’s words
The company describes four routes to growth: more specialties, branded drugs, international markets and owning more of its supply chain.
- Targets: set in May 2025; in February 2026 management said it would “drive toward our 2030 financial ambitions”, and in August that it was “building increased conviction” in them (Q1 2025 letter, Q4 2025 letter, Q2 2026 release). The Q3 release and call did not mention 2030; the CFO said more on long-term goals would come with the 2027 outlook (Q3 call transcript).
- Specialties: in 2025 it launched testosterone support, menopause and perimenopause care and lab testing, and said each “can eclipse $100 million in annual revenue in the future” (Q4 2025 letter). It began offering testosterone replacement therapy in 2026 (10-Q) and said on the Q3 call that its first peptide offerings would follow later in November (Q3 call transcript).
- Branded drugs: the Novo Nordisk collaboration (March 2026) and the Eli Lilly agreement announced in November (Lilly and Hims & Hers). In February it said: “In 2026, we expect to become a leading provider of branded GLP-1 medications in international markets” (Q4 2025 letter).
- International: it plans to expand “through a combination of organic investment and disciplined, strategic partnerships and acquisitions” (10-K); it bought Zava in 2025 and Eucalyptus in 2026 and launched the Hims brand in Germany in October.
- Supply chain: it bought manufacturing assets and lab and blood-sampling businesses, and paid for know-how to make peptide ingredients itself.
What the acquisitions cost
| Deal | When | Cost (disclosed) | Source |
|---|---|---|---|
| C S Bio manufacturing assets | Feb 2025 | Up to $39.1M in cash and stock, plus up to $32.7M more on earn-out conditions and the seller’s chief executive staying on, which is accounted for as pay | 10-Q |
| Trybe Labs (lab testing) | Feb 2025 | $5.1M in cash | 10-Q |
| Zava (UK/EU online doctor) | Jul 2025 | $258.0M accounting price, including $90.7M contingent | 10-K |
| YourBio Health (at-home blood sampling) | Jan 2026 | $153.0M accounting price, including $142.4M in cash | 10-Q |
| Eucalyptus (Australia, UK, Germany, Canada, Japan) | Jun 2026 | $968.5M accounting price: $225.0M upfront, $683.9M deferred over 18 months and a $59.6M earn-out estimate (up to $96.6M) | 10-Q |
| Peptide-ingredient know-how | 2026 | Up to $30.0M in milestone payments, $10.0M paid | 10-Q |
Is it working?
Abroad, acquisitions have lifted revenue quickly; at home, growth picked up in Q3; the cost shows in margins and in a lower profit outlook.
- International: revenue outside the US was $134.0M (6% of the total) in 2025 and $442.9M (20%) in the first nine months of 202611; Eucalyptus contributed about $135M in Q3, and the company expects at least $650M for 2026, up from $600M (Nov 9 call; 10-Q).
- United States: revenue grew 21% in Q3 after 16% in Q2 and 9% over nine months, led by the Hers brand, about 45% of US revenue in Q3 (10-Q).
- New specialties: revenue from testosterone, menopause, lab testing and peptides is not disclosed.
- Profitability: gross margin was 62% in the first nine months of 2026, against 75% a year earlier. The 2026 adjusted EBITDA outlook went from $300–375M in February to $257–277M in November, while the revenue outlook rose from $2.7–2.9B to $3.13–3.15B, including acquisitions (Q4 2025 release, Q3 2026 release). Morningstar analyst Keonhee Kim told Reuters that the branded mix would keep weighing on gross margins (Reuters via AOL).
- Subscribers: 2.79M at Sep 30, 2026, 13% more than a year earlier but 3.6% fewer than in June (10-Q).
What to watch for the strategy is in section 8: the 2027 outlook and any update to the 2030 targets, the launches of Lilly’s drugs and peptides, and rulings on compounding, telehealth prescribing and the FTC case.
8. What to watch
Last updated Nov 11, 2026. Reflects the 10-Q for Q3 2026 and company announcements through Nov 9, 2026.
| Date | Item | Source |
|---|---|---|
| Late Nov 2026 | First peptide offerings, per the company on the Q3 call; Eli Lilly’s Zepbound and Foundayo arriving on the platform in Q4 under the Nov 6 agreement | Q3 call transcript, Lilly and Hims & Hers |
| Dec 15, 2026 to Sep 8, 2027 | CEO Andrew Dudum’s 10b5-1 trading plan (a pre-arranged plan for trading company shares), adopted Sep 1, 2026, covers up to 2,836,791 shares | 10-Q |
| Dec 31, 2026 | Temporary federal flexibilities for prescribing controlled substances by telehealth are due to expire, unless extended; a final DEA rule is pending | 10-Q |
| Jan 14, 2027 | Court hearing on the company’s motion to dismiss the FTC case | 10-Q |
| Date not announced (Q4 2025 was reported Feb 23) | Q4 2026 results and the 2027 outlook, with which the CFO said more on long-term goals would come. The company guided to Q4 revenue of $875–895M and adjusted EBITDA of $70–90M | 8-K, Q3 call transcript |
| Quarterly through about Dec 2027 | Remaining Eucalyptus deferred instalments; $478.6M of deferred acquisition payments were due within 12 months at Sep 30, and most may be settled in stock, subject to contractual limits | 10-Q |
| No date set | An FDA final decision on the GLP-1 compounding proposal | FDA |
| About Jul 2027 (initial term ends) | The JPMorgan receivables facility; Feb 2028: the revolving credit facility | 10-Q |
| May 15, 2030 | The $1.0B convertible notes mature | 10-Q |
Valuation at each update
| Update | Close | Market value | EV | P/S | EV/sales | P/E | P/FCF | Revenue growth | FCF margin | Net cash (debt) | Basis |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2026 | $27.71 (Oct 23) | $6.5B | $7.0B | 2.5× | 2.7× | n/m | 104.9׆ | +28% | 2%† | ($524M) | 12 months to Jun 30, 2026 |
| Nov 11, 2026 | $19.13 (Nov 10) | $4.5B | $5.1B | 1.6× | 1.8× | n/m | 545.4׆ | +30% | 0%† | ($655M) | 12 months to Sep 30, 2026 |
Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 9, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 27, 2026: † Free cash flow includes $31M of customer prepayments (increase in contract liabilities) in the 12 months to Jun 30, 2026. Nov 11, 2026: † Free cash flow includes $14M of customer prepayments (increase in contract liabilities) in the 12 months to Sep 30, 2026. Oct 27, 2026 price: the Long View's stated close. Nov 11, 2026 price: Yahoo Finance and CNBC historical close.
Notes and calculations
-
(2,788K − 2,891K) ÷ 2,891K. ↩
-
Without the new foreign-currency add-back, Q3 adjusted EBITDA would be $78.3M: $82.388M − $4.064M. ↩
-
Change = 227.25M ÷ 204.79M − 1; annual rate = (227.25 ÷ 204.79)^(1/4) − 1; remaining ownership = 204.79 ÷ 227.25 × 1% (204.79 ÷ 234.40 × 1% at Sep 30, 2026); offset = 8.24M repurchased ÷ 30.69M issued. ↩
-
$ spent ÷ shares repurchased and retired. ↩
-
Stock pay ÷ revenue; first nine months of 2026: $143.5M ÷ $2,251.7M. ↩ ↩2
-
Deferred acquisition payable: $478.6M current + $84.5M non-current. Earn-out consideration: $86.6M current + $84.1M non-current. ↩ ↩2
-
2025 − first nine months of 2025 + first nine months of 2026. ↩
-
Operating cash flow − capital spending − capitalised software. ↩
-
Operating cash flow $180.1M − capital spending and capitalised software $171.9M. ↩
-
$605.6M + $106.6M. ↩
-
$442.9M ÷ $2,251.7M. ↩
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.
About Hims & Hers: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)